Abstract
The increasingly higher incidence of type 2 diabetes mellitus (DM2) in the children and adolescent populations implies the necessity of analysis of the effectiveness of currently available therapeutic modalities bearing in mind more aggressive specific complications of the disease in these groups of patients compared with the adult ones. Metformin is the sole oral hypoglycemic agent approved for the use in the children and adolescents with DM2. This paper reports the results of the application of different therapeutic modalities with the use of metformin in the children and adolescents with DM2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
